Premium
One‐week triple vs. quadruple therapy for Helicobacter pylori infection — a randomized trial
Author(s) -
Calvet X.,
Ducons J.,
Guardiola J.,
Tito L.,
Andreu V.,
Bory F.,
Guirao R.
Publication year - 2002
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2002.01278.x
Subject(s) - medicine , omeprazole , metronidazole , helicobacter pylori , gastroenterology , amoxicillin , clarithromycin , urea breath test , randomized controlled trial , breath test , pharmacotherapy , surgery , antibiotics , helicobacter pylori infection , microbiology and biotechnology , biology
Summary Background : Seven‐day triple therapy including omeprazole, clarithromycin and amoxicillin has become the treatment of choice for Helicobacter pylori infection. However, 7 days of classical quadruple therapy combining omeprazole, tetracycline, metronidazole and bismuth may be an alternative to triple therapy. Aim : To compare triple vs. quadruple therapy for H.pylori eradication. Methods : Three hundred and thirty‐nine patients with peptic ulcer and H. pylori infection were included in the study. Patients were randomized to receive omeprazole,20 mg, amoxicillin, 1 g, and clarithromycin, 500 mg, all b.d., or omeprazole, 20 mg b.d., tetracycline chloride, 500 mg, metronidazole, 500 mg, and bismuth subcitrate, 120 mg, all t.d.s. Cure was defined as a negative urea breath test at least 2 months after treatment. Results : Per protocol and intention‐to‐treat cure rates were 86%[95% confidence interval (CI), 80–91%] and 77% (95% CI, 70–83%) for triple therapy, and 89% (95% CI, 82–93%) and 83% (95% CI, 76–88%) for quadruple therapy. No significant differences between the groups were found in the cure rates, compliance or side‐effects. Conclusion : One‐week triple and quadruple therapy show similar results when used as first‐line eradication treatment.